Skip to Content
Stock Analyst Update

Mylan: Merger Creates Significant Generic Scale

We maintain our no-moat rating and await additional details on the Pfizer transaction.

Mentioned:

While normalized EPS came in notably above expectations, results were secondary to the announced tax-free divestiture combining Mylan (MYL) with Pfizer’s off-patent branded and generics business, Upjohn. The new entity will be the largest generic manufacturer with significant scale. As a result of the better-than-expected quarterly operating margins with the ramping of Fulphila (oncology) and Wixela (asthma), we are increasing our full-year non-GAAP EPS to $4.06 from $2.85. Although our second-quarter estimates were short, we do not see significant upside to our $20 fair value estimate, as the current operating margins are likely not sustainable based on the company's stand-alone (existing) pipeline. Mylan shares are up 13% intraday and trade near our fair value. We maintain our no-moat rating and await additional transaction details.

The all-stock, Reverse Morris Trust transaction effectively combines the two generics businesses, providing Mylan shareholders a 43% ownership of the new company. The new entity would displace Teva as the largest generic drug manufacturing company focused on developing complex generics, purposely de-emphasizing the North American generic market, which has been under duress. In our view, the stand-alone businesses were likely the weakest competitors in a highly competitive market and the combination is a logical step that would provide better footing in a market where scale is a critical differentiator. Further, the departure of Mylan key executives will hopefully increase operating transparency. Pro forma 2020 guidance includes roughly $250 million in synergies, with roughly $1 billion in synergies by 2023, which seem conservative considering Teva is on track to reduce $3 billion of operating expenses on a stand-alone basis. Management is targeting a debt/adjusted EBITDA ratio of 2.5 by 2021, from 3.9 for stand-alone Mylan with plans to initiate a dividend of at least 25% of free cash flow after the first quarter after the deal closes.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Soo Romanoff does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.